【YSPSAH 7178 交流专区】永信东南亚

scsiang82

13-06-2008: YSP plans RM40m plant in Vietnam
By Yantoultra Ngui Yichen


PETALING JAYA: Generic drug manufacturer YSP Southeast Asia Holdings Bhd (YSP) will allocate up to US$12 million (RM39.6 million) to build a pharmaceutical and veterinary products manufacturing plant in Vietnam by year-end as part of its strategy to spur overseas sales.

The main board listed firm, a unit of Taiwan-based Yung Shin Pharmaceutical Industries Co Ltd, said the new plant would enable YSP to cater to the northern Southeast Asia region besides tapping into Vietnam’s fast-growing population of more than 87 million.

“We see huge potential in that country, especially with its relatively young population. We will grow with the country and our presence there will be long term,” its president and group managing director Datuk Dr Frank Lee told The Edge Financial Daily yesterday.

The pharmaceutical firm expected its Vietnam plant, which is awaiting the green light from the Vietnamese authorities, to begin production before the end of next year and contribute up to 10% of its total revenue by 2010, said Lee.

YSP is likely to finance its investment in Vietnam mainly via borrowings, as its net cash position as at March 31, 2008 stood at RM12 million.

Lee said YSP’s proposed venture in Vietnam was a strategic move to expand its market regionally, given that Malaysia has a relatively small population of some 25 million. Overseas sales contributed 15% to YSP’s turnover of RM105 million in 2007.

The company, with a market capitalisation of about RM76.7 million, manufactures tablets, creams, capsules and medicated talcum at its plant in Bangi, Selangor. YSP manufactured almost 90% of its products locally and imported the remainder, said Lee.

“After the Vietnam plant is ready to tackle the market in the northern Southeast Asia region, Malaysia will serve as a strategic hub to serve the demand in the southern part,” he said, adding that YSP recently entered the Indonesian market by setting up a marketing firm in Jakarta.

The company current distribution network spans Singapore, Vietnam, Myanmar, the Philippines, Thailand, Cambodia and Indonesia. YSP recently kick-started its diversification into the traditional medicines sector with the purchase of a 60% stake in Sun Ten Pharmaceutical Manufacturing (M) Sdn Bhd.

Unlike contract manufacturing-based pharmaceutical firms, Lee said YSP had a varied clientele that ensured a diversified income source. Numbering some 200,000, YSP’s customers include general practitioners, pharmacies, private clinics, hospitals and livestock farms.

Shares of YSP, trading at a price-to-earnings ratio (P/E) of 6.1 times, closed three sen or 2.6% lower at RM1.13 yesterday in thin trade. The counter reached its 52-week high of RM1.58 on Oct 19, 2007 while its low was 97 sen on March 17, 2008.

http://www.theedgedaily.com/cms/content.jsp?id=com.tms.cms.article.Article_7fdb3496-cb73c03a-10837170-7ed399ba

icy97

永信东南亚附加股超购7%

财经新闻 财经  2011-08-02 11:09
（吉隆坡1日讯）永信东南亚（YSPSAH，7178，主板消费产品股）建议以3配1方式发行3326万144股附加股，获得7.10%超额认购。

根据文告，公众共认购3562万2978股新附加股，比原定供申请的数目超出236万2834股，或相等于7.10%。

资本开销1700万
该公司总裁兼集团董事经理拿督李芳信在文告中说，新附加股超额认购凸显出股东们大力支持集团的扩展计划及营运资本提升计划，以降低面对因借贷引致的经常性利息成本的压力。

他说，股东们乐于进一步参与公司的权益，也反映了他们对集团的展望及成长潜能具有信心。

“这对集团来说是个好预兆，使我们得以按照原订计划扩展及增长业务。”

永信东南亚计划拨出1700万令吉充作资本开销，包括扩大现有生产及研发设施，更换机器与配备。

工厂全线操作
李芳信表示，目前在雪兰莪州万宜的工厂几乎全线操作，年产量高达12亿粒供口服的固体药片及胶囊，以及大约12万公斤的外用药物如栓剂、药油、乳霜及乳胶。

透过发行附加股，该公司将能使工厂的口服固体药片及胶囊年产量增加60%以上至20亿粒，外用药物则倍增至28万公斤。[NanYang]

icy97

永信东南亚 中国修正药业 共用网络开拓新市场

财经新闻 财经  2011-09-15 12:21
（吉隆坡14日讯）永信东南亚（YSPSAH，7178，主板消费产品股）与中国修正药业集团，签下发展合作协议，通过双方建立的管道互相开发市场。

修正药业集团董事长修涞贵在签约仪式前，向记者公布上述消息。

“修正药业产品在大陆市场广为人知，而永信东南亚在东协市场的知名度则较高。这项合作是双赢的。”

上述合作下，修正药业和永信东南亚将互相引入适合的产品，通过双方市场管道把产品引进新市场。

“通过这项合作，我们能够通过永信东南亚把产品打入东协市场。同样的，永信东南亚可通过我们进军大陆市场。”

或在马合设厂
虽然修涞贵认为大马市场有一定潜力，不过，大马人对中国保健品和成药普遍接受度不高，仅较能接受产品如人参、灵芝、雪蛤等。

修涞贵表示：“永信东南亚和集团的理念比较一致，都是为消费者提供最佳药品。”

此外，他也透露双方有望深度合作。

“我们还有计划一些深度合作，如在大陆、东协或大马设厂。”

修正药业集团是中国第二大药厂，中国业务年营业额达300亿人民币（约142亿8200万令吉），海外业务年贡献则为2700万美元（约8224万2000令吉）。[NanYang]

icy97

SUMMARY OF KEY FINANCIAL INFORMATION

31/12/2011

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2011	31/12/2010	31/12/2011	31/12/2010
		$$'000	$$'000	$$'000	$$'000
1	Revenue	42,236	38,941	156,773	138,483
2	Profit/(loss) before tax	5,228	5,308	18,666	16,936
3	Profit/(loss) for the period	4,348	3,927	15,727	12,448
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,255	3,788	15,380	12,157
5	Basic earnings/(loss) per share (Subunit)	3.20	3.76	13.52	12.16
6	Proposed/Declared dividend per share (Subunit)	0.00	6.00	0.00	6.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6000		1.7100

icy97

Company Name	:	Y.S.P.SOUTHEAST ASIA HOLDING BERHAD
Stock Name	:	YSPSAH
Date Announced	:	03/04/2012

Type	:	Announcement
Subject	:	OTHERS
Description	:	PROPOSED FIRST AND FINAL DIVIDEND
Announcement Details/Table Section : Please be informed that the Board of Directors of Y.S.P. Southeast Asia Holding Bhd. ("the Company") had proposed the payment of a Single Tier First and Final Dividend of 6 sen per ordinary share of RM1.00 each for the financial year ended 31 December 2011, subject to shareholders' approval at the forthcoming Annual General Meeting of the Company. The entitlement date and date of payment of the dividend have yet to be determined. A further announcement will be made at a later date upon finalising the entitlement and payment date.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION

31/03/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/03/2012	31/03/2011	31/03/2012	31/03/2011
		$$'000	$$'000	$$'000	$$'000
1	Revenue	43,276	36,640	43,276	36,640
2	Profit/(loss) before tax	5,653	4,604	5,653	4,604
3	Profit/(loss) for the period	3,840	3,710	3,840	3,710
4	Profit/(loss) attributable to ordinary equity holders of the parent	3,882	3,583	3,882	3,583
5	Basic earnings/(loss) per share (Subunit)	2.92	3.56	2.92	3.56
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6300		1.6000

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/06/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/06/2012	30/06/2011	30/06/2012	30/06/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,307	38,324	88,583	74,964
2	Profit/(loss) before tax	5,911	2,909	11,564	7,513
3	Profit/(loss) for the period	4,547	2,658	8,387	6,368
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,542	2,570	8,424	6,153
5	Basic earnings/(loss) per share (Subunit)	3.41	2.54	6.33	6.10
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6100		1.6000

icy97

李芳信：嚴格監管專業運作‧永信立足大馬放眼東盟

投資致富  2012-08-23 14:45
永信藥品集團多年來以專業執著的精神堅守本業，漸進發展成為一家高科技的跨國公司。

先後在歐、美、亞、非等全球各地成功的開拓市場，馬來西亞是永信第一個在海外建立生產基地的國家。

踏入吉隆坡敦依斯邁花園某商廈的永信東南亞（YSPSAH，7178，主板消費品組）的辦公室，其掌舵人拿督李芳信博士披露，1987年，他從台灣來馬來西亞，當時主要著眼於行銷通路的建立。4年後，行銷網絡已穩定，公司決定在馬來西亞蓋廠。

他指出，坐落在雪州萬宜新鎮的製藥廠房，前後共擴建5次，而擴建的方式是循序漸進的，因為保守經營，風險相對減少。

永信東南亞於2004年在大馬股票交易所上市，2006年轉到主板，是目前唯一從台灣往外發展而跨國上市的藥廠。

準備進軍印尼藥品市場
目前，永信東南亞在雪州萬宜9英畝的地段，建立了5個廠區，生產的藥品有兩百多種，包括人用藥品、動物用藥品、保健產品、原料藥、衛生醫療藥品、特用化學品，它也進口和經銷中草藥、面部護理面膜和藥妝品。市場方面，以內銷為主力。

“我們已把生產動物用藥品的廠房轉移到越南，因為動物藥品的生產較簡單，產品出廠後再回銷大馬；大馬的廠房著重在高科技製藥。另外，我們已在印尼購置廠房，準備進軍印尼藥品市場。＂

李芳信強調，公司的生產程序經過重重嚴格把關，出廠的產品符合美國FDA及cGMP生產管制。

“製藥的過程，必須遵照流程，注重紀律；我們的管理規範相當固定。從初步的工序、檢查、生產、發單甚至報廢等，必須照本宣科，必須要有把關人員親自監察、簽名。因此，永信製藥20多年以來，從未面對藥品被召回的問題。我們講求信任、品質和專業服務，多年來在醫藥領域成功建立良好形象和崇高信譽。＂

永信東南亞在大馬擁有160名業務代表，客戶包括私人醫院、私人診所、藥房等達到2萬個。他說：“我們在東馬的古晉、亞庇也有營業據點，每一天平均收到近2千張訂單。從研發、生產、送貨、收錢，都是屬於公司一條龍作業。而這幾年來，我們都是24小時在生產。＂

大馬應協助廠商向外發展
他說，大馬政府的嚴格管制，提昇了其在國際間對藥品管制的良好形象，也建立了良好的藥物監管制度。

不過，他認為，大馬政府當局應該利用這種優勢，儘量協助廠商向外發展，甚至以東盟為發展基地，讓這裡的廠商有更好的擴展。他說，當初選擇在大馬設廠，也是因為大馬擁有較為健全的法規，而永信的經營理念中也重視法治精神。

李芳信表示，永信東南亞在大馬取得立足點，而後不斷擴建發展，確立了通路商地位，並放眼在東南亞地區擴大業務，靠的是公司成員的團結和向心力。他說，公司有明確的目標，員工遵循目標前進，講究專業運作，嚴守紀律，才能有今天的成功境地。（星洲日報／投資致富‧企業故事）

icy97

股海宝藏：永信东南亚 制药股宝石

股海宝藏 财经周刊 投资观点  2012-08-27 12:21
永信东南亚（YSPSAH，7178，主板消费产品股）是一家具有创意和领导地位的大马制药公司，于2004年6月在第二交易板上市，之后成功在2006年6月转到主要交易板。

今日，其集团生产的药品多样化，包括柜台人用药品、动物用药品、水产养殖药品等；区域公司和商业联盟遍布新加坡、越南、菲律宾、缅甸、柬埔寨、泰国、印尼、汶莱、寮国，以至斯里兰卡、非洲和中东国家。

公司大股东是拿督李芳信博士（集团董事经理），持有48%股权。

整体来说，虽然市场充斥着不确定性的挑战，达证券预测永信东南亚在2011-2014年，至少能够以10%的复率成长。这归功于它持续努力开发本地以及海外现有和新产品的范围，以致能够应付市场稳步上扬的药品需求。

台湾母公司支持
以永信东南亚1.06令吉的价钱，与其同行如发马（PHARMA，7081，主板贸服股）和APEX保健（AHEALTH，7090，主板消费产品股）比较，永信东南亚处于偏低的7.7倍本益比（是对手12倍的35%折价）和股价对账面价值0.7倍（为同业的60%折价），同时，还有不错的4%周息率和净现金630万令吉。

永信东南亚是一家有实力的药剂制造商，其背后支持者为台湾上市的母公司———永信药品工业（Yung ShinPharmaceutical Industry Co.Ltd.）。

永信东南亚的主要优势，为它能提供全面性的产品组合，多元顾客群和出色的研发能力。

由于有母公司的支持，永信东南亚也和全世界的分行一起通力加强其在大马和东南亚的地位。

马来西亚被选为主要的据点，以扩充公司在东南亚的市场。

同时，公司也在区域公司和商业联盟遍布新加坡、越南、柬埔寨、缅甸、印尼和泰国建立坚固的行销网络。永信东南亚集团和它子公司的协力合作，以将公司带到顶峰为目标。

顾客群多元化
永信东南亚有多元化、过万的顾客群，其中包括了医院、诊所、药剂行、兽医、禽畜、农场、水产养殖、饲料、普通药房乃至柜台销售。平均80%的业务是供应大马本地市场，其余20%销售则由海外贡献。

因此，永信东南亚有完整的传递网络和业务代表遍布大马，以服务其庞大的顾客群。

药剂业前景强劲
药剂业传统上由内需推动，不过在2002年，当大马成为药剂测试合作社（PIC/S）成员之后，这业务在出口取得了显着的突破。

根据卫生部（MOH）的报告，在2011年，我国的药剂产品出口额达到5.64亿令吉（年对年增加6%）。随着全球越来越接受PIC/S，它已成为我国本土制药商的一项重要条件。

因此，这两项推动力———内需和出口，现在将推动药剂业成为大马经济成长的策略性引擎。

卫生部乐观的认为，大马药剂业在2012年的出口将成长8%至6.1亿令吉。一个世界权威性的研究团体也预测，本地的药品和柜台药物市场将在2015年，增加到24.5亿令吉。

（来源：永信东南亚2011年报）
【业务回顾】
在2011年11月，卫生部给永信东南亚在万宜的工厂颁发了GMP（Good ManufacturingPractice）证书，这同时引申到其消毒产品（sterile products）。永信东南亚呈上了8项消毒产品申请，一旦成功注册，诸如眼药水和小份量针剂将在2012年底面市。

2011年4月，在越南DONG NAI的工业区，永信东南亚的药剂和动物用药品工厂也获得GMP证书。至今已有32项产品注册而工厂也在2011年9月开始生产。即将报废的主要药物版权，以及潜在的药品出口可能性将进一步擦亮大马药剂业的前景。

不管是本地或出口市场，前景依然亮丽；同时，永信东南亚的扩充计划正带来丰硕的果实，我们相信未来的业绩将会具有说服力，同时令人兴奋。

【成绩回顾】
永信东南亚2012首半年带来840万令吉盈利（按年起7.3%），主要是较高的业务（8860万令吉，按年起18.2%）。

达证券乐观的认为，永信东南亚的前景光明，随着主要药物版权的报废，将会占有更大的药物市场。

同时，其市场扩充到印尼，将更增加区域的需求，因此它将能更策略性的计划其药品的生产，以及出口的导向，最终将能在运作和物流方面的节省费用。[Nanyang]


文：慧眼

icy97

永信东南亚印尼设子公司

财经新闻 财经  2012-09-05 10:50
（吉隆坡4日讯）永信东南亚（YSPSAH，7178，主板消费产品股）宣布，以80万美元（约340万令吉）于印尼成立子公司。

根据文告，永信东南亚新加坡子公司———永信东南亚投资私人有限公司在今年7月13日，与印尼独立人士林志成（译名）联合成立PT YSP IndustriesIndonesia（简称PTYSPII）。

资料显示，永信东南亚投资支付的80万美元，相等于PT YSPII初步缴足股本75%，其余25%则来自林志成。[Nanyang]

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

Type of Securities	Warrants
Type of Expiry	Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion Price	Cash
Exercise/Strike/Conversion Price	MYR 1.4200
Exercise/ Conversion Ratio	1 warrant : 1 YSPSAH share
Settlement Type/ Convertible into	Physical (Shares)
Last Date & Time for Trading	19/11/2012 05:00 PM
Date & Time of Suspension	20/11/2012 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c	28/11/2012 04:00 PM
Date & Time of Expiry	05/12/2012 05:00 PM
Date & Time of Delisting	06/12/2012 09:00 AM

Attachments YSP Southeast - Notice to Warrantholders.pdf

icy97

永信东南亚净利挫48%

财经新闻 财经  2012-11-15 11:56
（吉隆坡14日讯）截至9月30日财年第3季，永信东南亚（YSPSAH，7178，主板消费产品股）净赚260万4000令吉，按年劲挫47.63%至497万2000令吉。

永信东南亚在文告中表示：“盈利下滑，主要外汇亏损、盈收款项折旧和借贷利息的支出。”

营业额方面，永信东南亚当季录得4555万1000令吉，较上财年同期的3957万3000令吉扬15.12%。

每股盈利则报1.96仙，上财年同期为4.06仙。

永信东南亚合计3季净利报1102万8000令吉，上财年同期为1112万5000令吉，跌幅为0.87%。

首3季营业额则报1亿3413万4000令吉，按年增17.11%。

至于每股盈利，9个月累计为8.29仙，上财年同期为10.16仙。[Nanyang]

SUMMARY OF KEY FINANCIAL INFORMATION 30/09/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/09/2012	30/09/2011	30/09/2012	30/09/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,551	39,573	134,134	114,537
2	Profit/(loss) before tax	4,696	5,925	16,260	13,438
3	Profit/(loss) for the period	2,651	5,011	11,038	11,379
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,604	4,972	11,028	11,125
5	Basic earnings/(loss) per share (Subunit)	1.96	4.06	8.29	10.16
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6200		1.6000

icy97

賺幅減少‧負債增加‧永信東南亞前景待觀察

熱股評析  2013-01-08 18:37
（吉隆坡8日訊）永信東南亞（YSPSAH，7178，主板消費品組）的區域拓展計劃仍未貢獻明顯盈利，卻面對賺幅減少、負債增加的利空，我們的看法趨向保守。

該公司2012年4月在印尼購地建廠，以拓展當地市場。目前來說，這家廠房仍處初步規劃階段，藥品製造類型、資本開銷等項目也尚未決定。

該公司最大營收來源仍是大馬工廠。這家廠房的產能達75%。除了獸藥將遷至越南，大馬工廠繼續生產其餘藥片、藥囊等藥品。

可能生產更多種藥品
2012財政年該公司的註冊藥品數量將從過去兩年的26種和32種，增至36種。來到2013財政年，該公司預計增加10種新藥品。
不
過，隨著大批藥品的專利到期，我們認為，該公司未來可能生產更多種藥品，因此10種新產品的估計顯然是趨向保守的。

越南廠房的產品將出口到不同的市場。目前，其產能僅有20至30%。隨著大馬廠房停產獸藥，越南工廠的產能料跟著提昇。目前，該公司投資1千700萬令吉在越南工廠。

最新的9個月業績顯示，該公司淨利賺幅正逐步縮減，從2011財政年的11.2%縮至現財政年的8.2%。同時，該公司為興建越南廠房，也借進更多貸款，從2011財政年的2千910萬令吉提高到現財政年的3千740萬令吉，按年增加29%。這兩個理由影響了我們的正面看法，因此選擇維持“守住＂評級。（星洲日報／財經）

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

Type	Announcement
Subject	OTHERS
Description	Y.S.P. SOUTHEAST ASIA HOLDING BERHAD ("YSPSAH") Additional investment in a subsidiary, Yung Shin (Philippines), Inc.
YSPSAH wishes to announce that the Company has increased its investment in the subsidiary, Yung Shin (Philippines), Inc. ("YS(P)") (incorporated in Philippines) from Peso8,313,540.00 to Peso19,999,940.00 by subscription of 1,168,646 shares of Peso10.00 each in YS(P) on 3 January 2013, maintaining its equity participation of 99.99% in the capital of YS(P). The total paid-up capital of YS(P) now stands at Peso20,000,000.00. The said additional investment of Peso11,686,460.00 was by way of capitalisation the retained earnings of YS(P) as dividend in lieu of cash. This announcement is dated 11 January 2013.

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

Type	Announcement
Subject	WINDING UP / RECEIVER & MANAGER / RESTRAINING ORDER / SPECIAL ADMINISTRATOR
Description	Y.S.P. SOUTHEAST ASIA HOLDING BERHAD MEMBERS’ VOLUNTARY WINDING-UP FOR THE WHOLLY-OWNED SUBSIDIARY, Y.S.P.SAH (VIETNAM) CO., LTD.
Y.S.P. Southeast Asia Holding Berhad (“the Company”) wishes to announce that its wholly-owned subsidiary, Y.S.P.SAH (Vietnam) Co., Ltd. (“Y.S.P.SAH(V)”) (incorporated in Brunei Darussalam) has been placed under Members’ Voluntary Winding-Up pursuant to Section 214(1) of the Companies Act, Cap 39 of Brunei on 12 December 2012 as part of the Company’s restructuring exercise and to wind-up dormant subsidiary. The paid-up capital of Y.S.P.SAH(V) is USD3.0 million. The principal activity of Y.S.P.SAH(V) is investment holding and it remains dormant since the internal restructuring as announced on 9 May 2011. Mr. Lee Kin Chee and Mr. Lee Kim Yan of Lee Corporatehouse Associates of No. 11, Regent Square, Simpang 150, Kiulap, Bandar Seri Begawan BE1518, Brunei Darussalam, be jointly and severally appointed liquidators for the Members’ Voluntary Winding-Up of Y.S.P.SAH(V). There is no material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2012 arising from the above liquidation. This announcement is dated 23 January 2013. (Remarks: The Company was duly notified by the liquidators in Brunei today on the commencement of liquidation.)

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/12/2012

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/12/2012	31/12/2011	31/12/2012	31/12/2011
		$$'000	$$'000	$$'000	$$'000

1	Revenue	46,476	42,236	180,610	156,773
2	Profit/(loss) before tax	3,891	5,228	20,151	18,666
3	Profit/(loss) for the period	2,533	4,348	13,571	15,727
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,600	4,255	13,628	15,380
5	Basic earnings/(loss) per share (Subunit)	1.95	3.13	10.24	13.24
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	6.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6400		1.6000

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

Type	Announcement
Subject	OTHERS
Description	PROPOSED FIRST AND FINAL DIVIDEND
Please be informed that the Board of Directors of Y.S.P. Southeast Asia Holding Bhd. ("the Company") has proposed the payment of a Single Tier First and Final Dividend of 6.5 sen per ordinary share of RM1.00 each for the financial year ended 31 December 2012, subject to shareholders' approval at the forthcoming Annual General Meeting of the Company. The entitlement date and date of payment of the dividend have yet to be determined. A further announcement will be made at a later date pertaining to the entitlement and payment dates. This announcement is dated 16 April 2013.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/03/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/03/2013	31/03/2012	31/03/2013	31/03/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	48,783	43,276	48,783	43,276
2	Profit/(loss) before tax	6,097	5,653	6,097	5,653
3	Profit/(loss) for the period	4,564	3,840	4,564	3,840
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,438	3,882	4,438	3,882
5	Basic earnings/(loss) per share (Subunit)	3.34	2.92	3.34	2.92
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6800		1.6400

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

Type	Announcement
Subject	OTHERS
Description	Y.S.P. SOUTHEAST ASIA HOLDING BERHAD - Direct major shareholder of Y.S.P. Southeast Asia Holding Bhd
Y.S.P. Southeast Asia Holding Bhd (“YSPSAH” or “the Company”) wishes to inform that the Company has received the Certificate of Merger dated 25 April 2013 issued by the Registrar of Corporate Affairs of the British Virgin Islands certifying the merger of YSP International Company Limited (“YSP International” as surviving company”) and YSP SEA Investment Company Limited (“YSP SEA Investment” as subsumed company). YSP International and YSP SEA Investment were incorporated in British Virgin Islands. In respect of the above, the Company wishes to announce that YSP International is now the direct major shareholder of YSPSAH instead of via YSP SEA Investment. The direct equity interest of YSP International in YSPSAH remains the same at 39.36% (52,365,605 shares). The ultimate major shareholder of YSPSAH remains unchanged as Yung Shin Global Holding Corporation (incorporated in Taiwan) via its 100% owned Yung Shin Pharmaceutical Industries Co. Ltd. (incorporated in Taiwan) which owns 100% YSP International. YSP International will make the necessary arrangement with Bursa Depository to resume and register their direct shareholdings in YSPSAH. For better understanding, please refer to the attached structure. (Remark: The Company was notified by YSP International on the aforesaid merger today.)

Attachments YSPSAH chart 16-5-2013.xls

icy97

Y.S.P.SOUTHEAST ASIA HOLDING BERHAD

EX-date	16/07/2013
Entitlement date	18/07/2013
Entitlement time	05:00:00 PM
Entitlement subject	First and Final Dividend
Entitlement description	First and final single tier dividend of 6.5 sen per ordinary share of RM1.00 each
Period of interest payment	to
Financial Year End	31/12/2012
Share transfer book & register of members will be	18/07/2013 to 18/07/2013 closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no	Mega Corporate Services Sdn. Bhd. Level 15-2, Bangunan Faber Imperial Court, Jalan Sultan Ismail, 50250 Kuala Lumpur. Tel no. 03-26924271
Payment date	05/08/2013
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	18/07/2013
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.065